


Elenbecestat

Chemical Properties

CAS No. :	1388651-30-6
Formula:	C ₁₉ H ₁₈ F ₃ N ₅ O ₂ S
Molecular Weight:	437.44
Storage:	Powder: -20°C for 3 years In solvent: -80°C for 1 year Actual storage temperature shall be subject to the COA.



Biological Description

Description	Elenbecestat (E2609) is an effective oral bioutilization and CNS penetrating ACE-1 inhibitor for the treatment of Alzheimer's disease.
Targets(IC50)	Beta-Secretase,BACE
In vitro	E2609 has been shown to reduce Ab production in the plasma, brain, and cerebrospinal fluid (CSF) of rodents.E2609 is a potent BACE1 inhibitor with an IC50 of ~7 nmol/L in cell-based assay.
In vivo	E2609 (0.3-30 mg/kg; p.o.) potently inhibits Ab1-40 and Ab1-42 production in the plasma and CSF of non-human primates.E2609 displays the plasma half-life of 12-16 hours after once daily dosing.

Solubility Information

Solubility	DMSO: 250 mg/mL (571.51 mM),Sonication is recommended. (< 1 mg/ml refers to the product slightly soluble or insoluble)
In vivo Formulation	10% DMSO+40% PEG300+5% Tween 80+45% Saline: 5 mg/mL (11.43 mM),Sonication is recommended. <i>Please add the solvents sequentially, clarifying the solution as much as possible before adding the next one. Dissolve by heating and/or sonication if necessary. Working solution is recommended to be prepared and used immediately. The formulation provided above is for reference purposes only. In vivo formulations may vary and should be modified based on specific experimental conditions.</i>

Preparing Stock Solutions

	1mg	5mg	10mg
1 mM	2.286 mL	11.4301 mL	22.8603 mL
5 mM	0.4572 mL	2.286 mL	4.5721 mL
10 mM	0.2286 mL	1.143 mL	2.286 mL
50 mM	0.0457 mL	0.2286 mL	0.4572 mL

Please select the appropriate solvent to prepare the stock solution, according to the solubility of the product in different solvents. Please use it as soon as possible.

Note: The dilution table applies only to solid products. For liquid products, please calculate the stock solution based on the stated concentration and/or density.

Reference

Kumar D, et al. Secretase inhibitors for the treatment of Alzheimer's disease: Long road ahead. *Eur J Med Chem.* 2018 Mar 25;148:436-452.

A single dose of the beta-secretase inhibitor, e2609, decreases CSF bace1 enzymatic activity in cynomolgus monkeys. *Alzheimer's & Dementia*, 8(4), P224.

Inhibitor · Natural Compounds · Compound Libraries · Recombinant Proteins

This product is for Research Use Only · Not for Human or Veterinary or Therapeutic Use

Tel: 781-999-4286 E_mail: info@targetmol.com Address: 34 Washington Street, Wellesley Hills, MA 02481